Basel, Switzerland, April 7, 2014 - Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign.
星期一, 2014, 4月 7 - 07:25
One million antimalarial treatments donated by Novartis, matching one million treatments funded through Malaria No More's Power of One campaign
Power of One enables the public to fund malaria tests and treatments for children in Africa through online and mobile technology
Today marks World Health Day, focusing on vector-borne diseases, of which malaria is the most deadly
Basel, Switzerland, April 7, 2014 - Novartis announced today that two million treatments of its pediatric antimalarial are arriving in Zambia thanks to the ongoing efforts of the company in collaboration with Malaria No More's Power of One campaign. Zambia is the first beneficiary country of this campaign sponsored by Novartis. One million treatments of Coartem® Dispersible have been funded through public donations and Novartis matched these with a further one million treatments. These antimalarials will reduce the disease burden in Zambia, which accounts for up to 40% of infant mortality in that country.
"Although the incidence of malaria has decreased, the disease still kills a child every minute in Africa," said Joseph Jimenez, CEO of Novartis. "Our commitment to Power of One reflects our company's long-term efforts to fight malaria and Novartis remains dedicated to controlling and ultimately eliminating this deadly disease."
Power of One is a global digital fundraising campaign that enables people around the world to help end child deaths from malaria, a preventable and treatable disease. This fatal disease has been recognized by the World Health Organization as a priority area of public health. This year's World Health Day focuses on vector-borne diseases, and malaria is the most deadly.
The campaign, which launched to the public in September 2013, uses social, mobile, and e-commerce technologies, enabling the public to purchase treatments for children in Zambia. Donors are able to share information with their social networks and encourage friends to donate.
"One and a half million treatments are already on the ground in Zambia thanks to the Power of One campaign, with a further 500,000 anticipated in the coming weeks," said Martin Edlund, CEO, Malaria No More. "Power of One is resonating with the general public, and their donations will help us ensure that children in Zambia will have access to the treatment they need."
Novartis is supporting the campaign financially and has pledged to match up to 1 million treatments funded by the public every year through 2015. For more than a decade, the Novartis Malaria Initiative has worked to improve access to treatment, help communities deliver better healthcare and has invested in research and development into the next generation of antimalarials. Since 2009, Novartis has delivered over 600 million treatments, of which more than 200 million were treatments developed specifically for children, without profit to malaria-endemic countries. Never before have so many pediatric treatments been distributed in such a short timeframe to children suffering from malaria.
About Power of One Malaria No More's Power of One campaign offers the global public and corporations the opportunity to help end malaria deaths one dollar and one child at a time. Every dollar donated funds a full treatment course for a child diagnosed with malaria in Africa. Malaria No More is grateful for the support and contributions of Power of One partners: Novartis, Alere, the Zambian Government, 21st Century Fox, AGFUND, AHAlife.com, the Bill & Melinda Gates Foundation, Causes.com, Havas Worldwide, John Snow, Inc., Newman's Own Foundation, PATH/MACEPA, Peace Corps, Time Warner, Twitter, the United States President's Malaria Initiative, Venmo, West, and more. Additional information is available at www.Po1.org.
About the Novartis Malaria Initiative The Novartis Malaria Initiative is one of the largest access-to-medicine programs in the healthcare industry. Moving forward, Novartis is committed to working towards malaria elimination by driving the development of next-generation antimalarials, with two new classes of drugs currently in clinical development. The most advanced compound is in Phase II clinical trials. For more information, please visit: www.malaria.novartis.com
Disclaimer This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "expects," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.
About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.